Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars Should Face Patent Challenges Only After Approval - Novartis

This article was originally published in The Pink Sheet Daily

Executive Summary

But Novartis’ idea is not reflected in any biosimilars legislation introduced to date.
Advertisement

Related Content

Patent Challenge Mechanism For FOBs Should Be Scrapped, FTC Says
Patent Challenge Mechanism For FOBs Should Be Scrapped, FTC Says
Follow-On Biologics Study By FTC Aims “To Strike The Right Balance”
Follow-On Biologics Study By FTC Aims “To Strike The Right Balance”
Biogenerics Bill From Reps. Eshoo And Barton “Expects” Limits On Substitution

Topics

Advertisement
UsernamePublicRestriction

Register

PS066936

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel